Imagine a
world without allergies
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead development programs include treatments for birch pollen, grass pollen and peanut allergies.
Desentum’s products are investigational and not approved for marketing in any region.
Technology
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
Desentum
Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
News
Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2...
Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy
The shareholders of Desentum Oy are summoned to the company’s Annual General Meeting to be held on June 23rd, 2025, at 10.00 (EEST) in Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo.
Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the...